Compare Stocks: VBIO, FBLG, BRTX, and ERNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRTX Biorestorative Therapies	$0.21 +4.5%	$0.34	$0.16 ▼ $1.89	$5.35M	0.79	8.18 million shs	309,822 shs
ERNA Ernexa Therapeutics	$4.39 -3.1%	$5.78	$3.18 ▼ $71.50	$5.14M	2.57	885,062 shs	42,844 shs
FBLG FibroBiologics	$1.03 +5.1%	$0.85	$0.62 ▼ $12.80	$6.86M	1.2	249,900 shs	122,289 shs
VBIO Valion Bio, Inc. Common Stock	$0.31 +7.6%	$0.48	$0.25 ▼ $5.60	$1.29M	1.85	375,403 shs	1.35 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRTX Biorestorative Therapies	-1.47%	+1.57%	-41.74%	+1.77%	-86.14%
ERNA Ernexa Therapeutics	+7.60%	+31.30%	-25.25%	-62.28%	-89.34%
FBLG FibroBiologics	+0.39%	+23.97%	+6.91%	-10.91%	-91.59%
VBIO Valion Bio, Inc. Common Stock	+0.91%	-8.86%	-43.42%	-73.82%	-90.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRTX Biorestorative Therapies	$0.21 +4.5%	$0.34	$0.16 ▼ $1.89	$5.35M	0.79	8.18 million shs	309,822 shs
ERNA Ernexa Therapeutics	$4.39 -3.1%	$5.78	$3.18 ▼ $71.50	$5.14M	2.57	885,062 shs	42,844 shs
FBLG FibroBiologics	$1.03 +5.1%	$0.85	$0.62 ▼ $12.80	$6.86M	1.2	249,900 shs	122,289 shs
VBIO Valion Bio, Inc. Common Stock	$0.31 +7.6%	$0.48	$0.25 ▼ $5.60	$1.29M	1.85	375,403 shs	1.35 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRTX Biorestorative Therapies	-1.47%	+1.57%	-41.74%	+1.77%	-86.14%
ERNA Ernexa Therapeutics	+7.60%	+31.30%	-25.25%	-62.28%	-89.34%
FBLG FibroBiologics	+0.39%	+23.97%	+6.91%	-10.91%	-91.59%
VBIO Valion Bio, Inc. Common Stock	+0.91%	-8.86%	-43.42%	-73.82%	-90.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRTX Biorestorative Therapies	1.00	Sell	N/A	N/A
ERNA Ernexa Therapeutics	2.00	Hold	$30.00	583.37% Upside
FBLG FibroBiologics	1.80	Reduce	$73.00	6,987.38% Upside
VBIO Valion Bio, Inc. Common Stock	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest VBIO, FBLG, BRTX, and ERNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2026	FBLG FibroBiologics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00 ➝ $6.00
8/4/2026	FBLG FibroBiologics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Underperform
7/24/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/17/2026	ERNA Ernexa Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	VBIO Valion Bio, Inc. Common Stock	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/7/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
6/17/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/1/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
5/27/2026	BRTX Biorestorative Therapies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
5/11/2026	ERNA Ernexa Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRTX Biorestorative Therapies	$360K	14.86	N/A	N/A	$0.04 per share	5.25
ERNA Ernexa Therapeutics	$580K	8.86	N/A	N/A	$7.64 per share	0.57
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$1.85 per share	N/A
VBIO Valion Bio, Inc. Common Stock	$780K	1.65	N/A	N/A	$6.65 per share	0.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRTX Biorestorative Therapies	-$14.24M	-$1.07	N/A	N/A	N/A	-3,088.27%	-508.42%	-230.94%	8/11/2026 (Estimated)
ERNA Ernexa Therapeutics	-$14.08M	-$14.35	N/A	N/A	N/A	N/A	-305.93%	-169.86%	8/12/2026 (Estimated)
FBLG FibroBiologics	-$18.65M	-$5.19	N/A	N/A	N/A	N/A	-536.78%	-225.12%	10/30/2026 (Estimated)
VBIO Valion Bio, Inc. Common Stock	-$8.88M	-$6.68	N/A	N/A	N/A	N/A	-138.10%	-63.67%	8/17/2026 (Estimated)

Latest VBIO, FBLG, BRTX, and ERNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q2 2026	VBIO Valion Bio, Inc. Common Stock	-$408.00	N/A	N/A	N/A	$0.46 million	N/A
8/11/2026	Q2 2026	BRTX Biorestorative Therapies	-$0.15	N/A	N/A	N/A	$0.60 million	N/A
8/6/2026	Q2 2026	ERNA Ernexa Therapeutics	-$3.30	-$3.40	-$0.10	-$3.40	N/A	N/A
7/31/2026	Q2 2026	FBLG FibroBiologics	-$0.93	-$0.66	+$0.27	-$0.66	N/A	N/A
5/20/2026	Q1 2026	ERNA Ernexa Therapeutics	-$1.95	-$6.95	-$5.00	-$6.95	N/A	N/A
5/14/2026	Q1 2026	BRTX Biorestorative Therapies	-$0.20	-$0.19	+$0.01	-$0.12	$0.31 million	$0.02 million
5/14/2026	Q1 2026	VBIO Valion Bio, Inc. Common Stock	N/A	-$2.23	N/A	-$2.23	N/A	N/A
5/11/2026	Q1 2026	ERNA Ernexa Therapeutics	-$1.95	-$6.95	-$5.00	-$6.95	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRTX Biorestorative Therapies	N/A	N/A	N/A	N/A	N/A
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	N/A
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A
VBIO Valion Bio, Inc. Common Stock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRTX Biorestorative Therapies	N/A	2.35	2.35
ERNA Ernexa Therapeutics	N/A	2.01	2.01
FBLG FibroBiologics	N/A	2.64	2.64
VBIO Valion Bio, Inc. Common Stock	0.62	3.31	3.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRTX Biorestorative Therapies	69.38%
ERNA Ernexa Therapeutics	70.55%
FBLG FibroBiologics	N/A
VBIO Valion Bio, Inc. Common Stock	4.25%

Insider Ownership

Company	Insider Ownership
BRTX Biorestorative Therapies	13.60%
ERNA Ernexa Therapeutics	0.53%
FBLG FibroBiologics	7.30%
VBIO Valion Bio, Inc. Common Stock	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRTX Biorestorative Therapies	7	25.48 million	22.01 million	Not Optionable
ERNA Ernexa Therapeutics	10	1.17 million	1.16 million	No Data
FBLG FibroBiologics	10	6.66 million	6.17 million	N/A
VBIO Valion Bio, Inc. Common Stock	10	4.15 million	4.05 million	Not Optionable

VBIO, FBLG, BRTX, and ERNA Headlines

Recent News About These Companies

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Up 70.0% in July

July 31, 2026 | americanbankingnews.com

Valion Bio, Inc.

July 22, 2026 | cnn.com

Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

July 22, 2026 | prnewswire.com

World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market

July 20, 2026 | prnewswire.com

Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion

July 14, 2026 | prnewswire.com

AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS

June 25, 2026 | prnewswire.com

VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME

May 19, 2026 | prnewswire.com

Valion Bio, Inc.: Valion Bio Reports First Quarter 2026 Financial Results

May 15, 2026 | finanznachrichten.de

Valion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling work

May 14, 2026 | seekingalpha.com

Valion Bio Inc. (VBIO) Q1 2026 Earnings Call Prepared Remarks Transcript

May 14, 2026 | seekingalpha.com

Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform

May 14, 2026 | prnewswire.com

VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

May 14, 2026 | prnewswire.com

Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026

May 11, 2026 | prnewswire.com

Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™

May 6, 2026 | prnewswire.com

VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION

May 5, 2026 | prnewswire.com

Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple ...

April 23, 2026 | finance.yahoo.com

Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

April 23, 2026 | prnewswire.com

Sheryle Bolton Purchases 10,000 Shares of Tivic Health Systems (NASDAQ:TIVC) Stock

April 21, 2026 | insidertrades.com

Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th

April 15, 2026 | prnewswire.com

Tivic Health Systems, Inc.

April 3, 2026 | edition.cnn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO, FBLG, BRTX, and ERNA Company Descriptions

Biorestorative Therapies NASDAQ:BRTX

$0.21 +0.01 (+4.48%)

Closing price 04:00 PM Eastern

Extended Trading

$0.21 +0.00 (+1.90%)

As of 06:11 PM Eastern

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Ernexa Therapeutics NASDAQ:ERNA

$4.39 -0.14 (-3.09%)

Closing price 04:00 PM Eastern

Extended Trading

$4.56 +0.17 (+3.76%)

As of 06:11 PM Eastern

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

FibroBiologics NASDAQ:FBLG

$1.03 +0.05 (+5.10%)

Closing price 04:00 PM Eastern

Extended Trading

$1.00 -0.03 (-2.91%)

As of 07:13 PM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Valion Bio, Inc. Common Stock NASDAQ:VBIO

$0.31 +0.02 (+7.64%)

As of 04:00 PM Eastern

Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VBIO, FBLG, BRTX, and ERNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VBIO, FBLG, BRTX, and ERNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VBIO, FBLG, BRTX, and ERNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO, FBLG, BRTX, and ERNA Company Descriptions

Biorestorative Therapies NASDAQ:BRTX

Ernexa Therapeutics NASDAQ:ERNA

FibroBiologics NASDAQ:FBLG

Valion Bio, Inc. Common Stock NASDAQ:VBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VBIO, FBLG, BRTX, and ERNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VBIO, FBLG, BRTX, and ERNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VBIO, FBLG, BRTX, and ERNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO, FBLG, BRTX, and ERNA Company Descriptions

Biorestorative Therapies NASDAQ:BRTX

Ernexa Therapeutics NASDAQ:ERNA

FibroBiologics NASDAQ:FBLG

Valion Bio, Inc. Common Stock NASDAQ:VBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools